You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,320,997


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,320,997
Title:Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
Abstract: A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject\'s risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality. The pharmaceutical composition may be adapted to be administered to a human subject.
Inventor(s): Lockwood; Samuel Fournier (Lake Linden, MI), O\'Malley; Sean (Honolulu, HI), Watumull; David G. (Honolulu, HI), Hix; Laura M. (San Francisco, CA), Jackson; Henry (Honolulu, HI), Nadolski; Geoff (Kaaawa, HI)
Assignee: Cardax Pharmaceuticals, Inc. (Aiea, HI)
Application Number:10/793,692
Patent Claims:1. A pharmaceutical composition comprising: a carotenoid analog or derivative having the structure ##STR00092## where each R.sup.3 is independently hydrogen or methyl; where each Y is independently O or H.sub.2; where each R is independently OR.sup.1 or R.sup.1; where each R.sup.1 is independently -alkyl-NR.sup.2.sub.3.sup.+, -alkyl-NR.sup.2.sub.2, -aryl-NR.sup.2.sub.3.sup.+, -alkyl-CO.sub.2.sup.-, -aryl-CO.sub.2.sup.-, -alkyl-CO.sub.2H, -alkyl-CO.sub.2R.sup.6, -alkyl-CO.sub.2R.sup.7, --OR.sup.7, -amino acid-NH.sub.2, -amino acid-NH.sub.3.sup.+, -phosphorylated amino acid-NH.sub.3.sup.+, polyethylene glycol, dextran, H, alkyl, aryl, -alkyl-O--PO.sub.2-O--alkyl-NR.sup.2.sub.3.sup.+, ##STR00093## where each R.sup.2 is independently H, alkyl, or aryl; wherein R' is alkyl-O, alkyl, or aryl; wherein each R.sup.5 is independently H, alkyl, benzyl, or alkali salt; wherein R.sup.6 is alkyl, --CH.sub.2--CH(OH)--CH.sub.2--O--PO.sub.2--O-alkyl-NR.sup.2.sub.3.sup.+, ##STR00094## wherein R.sup.7 is -alkyl-NR.sup.2.sub.3.sup.+, -aryl-NR.sup.2.sub.3.sup.+, -alkyl-CO.sub.2.sup.-, -aryl-CO.sub.2.sup.-, -amino acid-NH.sub.3.sup.+, -phosphorylated amino acid-NH.sub.3.sup.+, polyethylene glycol, dextran, H, alkyl, ##STR00095## or aryl; and at least one biologically inactive carrier.

2. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00096## where each X is independently -alkyl-NR.sup.4.sub.3.sup.+, -alkyl-NR.sup.4.sub.3.sup.+, -alkyl-CO.sub.2.sup.-, -aryl-CO.sub.2.sup.-, -amino acid-NH.sub.3.sup.+, -phosphorylated amino acid-NH.sub.3.sup.+, polyethylene glycol, dextran, H, alkyl, aryl, or alkali salt, and where each R.sup.4 is independently H, alkyl, or aryl; where each R' is independently -alkyl-O, alkyl, or aryl; and where n is between 0 and 12.

3. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00097## where each X is independently -alkyl-NR.sup.4.sub.3.sup.+, -aryl-NR.sup.4.sub.3.sup.+, -alkyl-CO.sub.2.sup.-, -aryl-CO.sub.2.sup.-, -amino acid-NH.sub.3.sup.+, -phosphorylated amino acid-NH.sub.3.sup.+, polyethylene glycol, dextran, H, alkyl, aryl, or alkali salt, and where each R.sup.4 is independently H, alkyl, or aryl; where each R' is independently -alkyl-O, alkyl, or aryl; and where n is between 0 and 12.

4. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00098##

5. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00099##

6. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00100##

7. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00101##

8. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00102##

9. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00103##

10. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00104##

11. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00105##

12. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00106##

13. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00107##

14. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00108##

15. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00109##

16. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00110##

17. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00111##

18. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00112##

19. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00113##

20. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00114##

21. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00115##

22. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00116##

23. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00117##

24. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00118##

25. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00119##

26. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00120##

27. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00121##

28. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00122##

29. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00123##

30. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00124##

31. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00125##

32. The pharmaceutical composition of claim 1, wherein each R.sup.1 is independently ##STR00126## ##STR00127## ##STR00128## ##STR00129##

33. The pharmaceutical composition of claim 1, further comprising one or more excipients.

34. The pharmaceutical composition of claim 1, wherein the biologically inactive carrier comprises a saccharide.

35. The pharmaceutical composition of claim 1, wherein the biologically inactive carrier comprises a sugar alcohol.

36. The pharmaceutical composition of claim 1, wherein the biologically inactive carrier comprises a cellulose preparation.

37. The pharmaceutical composition of claim 1, wherein the biologically inactive carrier comprises calcium phosphate.

38. The pharmaceutical composition of claim 1, further comprising human serum albumin.

39. The pharmaceutical composition of claim 1, further comprising human serum albumin, wherein human serum albumin is in molar excess of the carotenoid analog or derivative.

40. The pharmaceutical composition of claim 1, further comprising one or more preservatives.

41. The pharmaceutical composition of claim 1, further comprising a co-antioxidant.

42. The pharmaceutical composition of claim 1, further comprising one or more stabilizers.

43. The pharmaceutical composition of claim 1, further comprising one or more auxiliaries.

44. The pharmaceutical composition of claim 1, further comprising one or more binders.

45. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered orally.

46. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of one or more tablets.

47. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of one or more softgels.

48. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of one or more lozenges.

49. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of one or more capsules.

50. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of one or more dragees.

51. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in aerosolized form.

52. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of one or more suppositories.

53. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of an oily injection suspension.

54. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of an aqueous injection suspension.

55. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of an emulsion, the emulsion comprising water, oil and soybean lecithin.

56. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered by oral gavage.

57. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered in the form of a solution.

58. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered parenterally.

59. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered subcutaneously.

60. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered intravenously.

61. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted for intracoronary administration.

62. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered rectally.

63. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered by intramuscular injection.

64. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered by intraperitoneal injection.

65. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is adapted to be administered transdermally.

66. The pharmaceutical composition of claim 1, wherein each R.sup.1is independently: ##STR00130## wherein each R is independently H, alkyl, aryl, benzyl, or alkali salt.

67. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00131##

68. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00132##

69. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00133## wherein each R.sup.1 is independently -alkyl-CO.sub.2R.sup.6, ##STR00134## wherein each R.sup.5 is independently H, alkyl, benzyl, or alkali metal; and wherein each R.sup.6 is independently ##STR00135##

70. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00136## wherein each R.sup.1 is independently -alkyl-CO.sub.2R.sup.6, ##STR00137## wherein each R.sup.5 is independently H, alkyl, benzyl, or alkali metal; and wherein each R.sup.6 is independently ##STR00138##

71. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00139##

72. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00140##

73. The pharmaceutical composition of claim 1, wherein the carotenoid analog or derivative has the structure ##STR00141##

74. A pharmaceutical composition comprising: a carotenoid analog or derivative having the structure ##STR00142## where each R.sup.3 is independently hydrogen or methyl; where each Y is independently O or H.sub.2; where each R is independently OR.sup.1 or R.sup.1; where each R.sup.1 is independently -alkyl-NR.sup.2.sub.3.sup.+, -alkyl-NR.sup.2.sub.2, -aryl-NR.sup.2.sub.3.sup.+, aryl-CO.sub.2.sup.-, -alkyl-CO.sub.2R.sup.6, -alkyl-CO.sub.2R.sup.7, -amino acid-NH.sub.2, -amino acid-NH.sub.3.sup.+, -phosphorylated amino acid-NH.sub.3.sup.+, -alkyl-O--PO.sub.2--O-alkyl-NR.sup.2.sub.3.sup.+, ##STR00143## where each R.sup.2 is independently H, alkyl, or aryl; wherein each R.sup.5 is independently H, alkyl, benzyl, or alkali salt; wherein R.sup.6 is --CH.sub.2--CH(OH)--CH.sub.2--O--PO.sub.2--O-alkyl-N.sup.2.sub.3.sup.+, ##STR00144## wherein R.sup.7 is alkyl-NR.sup.2.sub.3.sup.+, -aryl-NR.sup.2.sub.3.sup.+, -alkyl-CO.sub.2.sup.-, -aryl-CO.sub.2, -amino acid NH.sub.3.sup.+, or -phosphorylated amino acid-NH.sub.3.sup.+; and at least one biologically inactive carrier.

Details for Patent 7,320,997

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2022-07-29
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2022-07-29
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2022-07-29
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 08/15/1978 ⤷  Try a Trial 2022-07-29
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 02/17/1995 ⤷  Try a Trial 2022-07-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.